LB Pharmaceuticals (NASDAQ:LBRX) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
LB Pharmaceuticals (NASDAQ:LBRX) had its "sell (e)" rating reaffirmed by analysts at
Weiss Ratings.
LB Pharmaceuticals (NASDAQ:LBRX) had its price target raised by analysts at Stifel Nicolaus from $27.00 to $35.00. They now have a "buy" rating on the stock.
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)